Terlipressin for Hepatorenal Syndrome: Fixing the Circulation to Rescue the Kidneys

The problem

Hepatorenal syndrome (HRS) is one of the more counterintuitive emergencies in medicine: the kidneys shut down even though they are structurally normal. It develops in advanced liver disease — typically cirrhosis with ascites — and its cause is circulatory, not renal. In advanced cirrhosis, the blood vessels around the gut (the splanchnic circulation) become abnormally dilated. This effectively pools blood away from the rest of the body, so the kidneys sense reduced blood flow and progressively stop filtering. Untreated, HRS carries a grim prognosis.

Why terlipressin fits

If the problem is a dilated, "leaky" circulation robbing the kidneys of blood flow, the fix is to re-tighten that circulation — and that is exactly what terlipressin does. Terlipressin is a long-acting analog of vasopressin that acts on V1 receptors to constrict the over-dilated splanchnic vessels. Tightening them redistributes blood volume, raises the effective pressure reaching the kidneys, and can restore kidney function, reversing the syndrome in a meaningful proportion of patients.

Terlipressin is designed as a slow-release prodrug: after injection it gradually releases active lysine-vasopressin over hours, giving a steadier effect than short-acting vasopressin and allowing intermittent bolus dosing or infusion on the ward or ICU. It received US FDA approval in 2022 for HRS with rapid kidney decline and has long been used elsewhere.

Why albumin is part of the recipe

Terlipressin is almost always paired with intravenous albumin, a blood protein that helps expand and hold circulating volume. The combination addresses the circulatory problem from two directions — constricting the dilated vessels (terlipressin) and supporting blood volume (albumin) — and this pairing is standard practice.

The risks that shape its use

Because terlipressin constricts vessels throughout the body, it can reduce blood flow to the fingers, toes, skin, and intestines (ischemia), cause fluid overload and low sodium, and — importantly in this fragile population — it has been associated with respiratory complications. This is why patients are carefully selected, monitored closely, and why some are not suitable candidates. Where terlipressin isn't available, alternatives such as norepinephrine (in an ICU) or midodrine plus octreotide are used to achieve the same hemodynamic goal.

The honest framing

Terlipressin treats the circulation, not the failing liver that caused HRS. Kidney function can relapse, and for many patients the definitive treatment is liver transplantation — with terlipressin serving as a bridge to improve kidney function while transplant is evaluated. It is a hospital-only, prescription therapy managed by hepatology and critical-care teams, never something used outside supervised care.

This article is educational and does not constitute medical advice.